NORRISTOWN, Pa., June 8 /PRNewswire/ -- RheoGene Inc. announced today that it has granted an exclusive, worldwide license to New England Biolabs (NEB) (Beverly, Mass.) to develop and distribute research kits and related products based on RheoGene's RheoSwitch inducible gene regulation technology. The agreement also grants NEB nonexclusive rights to develop novel combination products for the research market that incorporate RheoSwitch technology and NEB proprietary technologies.
This agreement will make RheoGene's RheoSwitch(TM) system broadly available to the research community through NEB's global distribution network. Future product introductions will include the RheoPlex(TM) multigene regulation system for independent regulation of more than one gene at a time.
"There were several reasons that NEB was the best choice to market our RheoSwitch System," said Tom Tillett, president and CEO of RheoGene. "NEB's excellent reputation for conducting first-rate science, the high quality of their products and customer service, and the strong support and enthusiasm from all key parts of the NEB organization contributed to our decision. This, combined with their commitment to establish the RheoSwitch System as the premiere inducible gene regulation system, made NEB the best partnering choice and is another significant milestone for RheoGene as we transition from a platform tools company to a human therapeutics company."
"We are very pleased to be able to add RheoGene's inducible gene expression technology into our product line," said Dr. Larry McReynolds, Director of Eukaryotic Research at New England Biolabs. "This technology fits well with our research base and internal expertise. We look forward to increasing the availability of the RheoSwitch and RheoPlex systems to the research community as well as to developing future innovative combination products."
RheoSwitch inducible gene expression technology precisely regulates the timing and level of transgene expression in eukaryotic cells through the highly specific interaction of RheoChem(TM) ligand inducers with RheoCept(TM) protein receptors. The RheoSwitch system features tight regulation, rheostatic control, and an expression range up to levels equivalent to the strongest viral promoters. The RheoSwitch system is ideal for production of 'difficult-to-express' and cytotoxic proteins.
The companies anticipate that NEB's first RheoSwitch(TM) product will be available by the end of this year. Financial terms were not disclosed.
RheoGene Inc. is the source of advanced products, applications and technologies that regulate gene expression for the development of safe and effective therapeutics. RheoGene delivers customized inducible gene expression products for pharmaceutical discovery, human therapeutics, biotherapeutics production and agriculture. RheoGene Inc. is a wholly owned subsidiary of RheoGene Holdings Inc. with operations in Norristown, Pa. For more information, visit http://www.rheogene.com/ .
New England Biolabs leads the industry in the discovery and production of enzymes for molecular biology applications. Established in the mid-1970's, New England Biolabs now offers the largest selection of recombinant and native enzymes for genome research and continues to expand its product offerings into areas related to proteomics and drug discovery. New England Biolabs is a privately held company headquartered in Beverly, Mass. and has extensive worldwide distribution through a network of exclusive distributors, agents and four subsidiaries located in Canada, China, Germany and the United Kingdom. For more information about New England Biolabs visit http://www.neb.com/ .
RheoGene Contact: NEB Contact:
Lorraine Keller, Ph.D Fiona Stewart, Ph.D.
Vice President, Marketing Business Development
CONTACT: Michele Baum
PHONE: (412) 647-3555
FAX: (412) 624-3184
University of Pittsburgh Medical Center
CONTACT: Michele Baum of University of Pittsburgh Medical Center,+1-412-647-3555, or Fax +1-412-624-3184, or BaumMD@upmc.edu ; or LorraineKeller, Ph.D, Vice President, Marketing of RheoGene, +1-215-205-6084; or FionaStewart, Ph.D., Business Development of NEB, +1-978-998-7297